Virax Biolabs Group Stock Price To Earnings To Growth
| VRAX Stock | USD 1.97 0.10 4.83% |
Virax Biolabs Group fundamentals help investors to digest information that contributes to Virax Biolabs' financial success or failures. It also enables traders to predict the movement of Virax Stock. The fundamental analysis module provides a way to measure Virax Biolabs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Virax Biolabs stock.
Virax | Price To Earnings To Growth |
Virax Biolabs Group Company Price To Earnings To Growth Analysis
Virax Biolabs' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Virax Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Virax Biolabs is extremely important. It helps to project a fair market value of Virax Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Virax Biolabs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Virax Biolabs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Virax Biolabs' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Virax Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Virax Biolabs Group has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Virax Fundamentals
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (42.54) % | ||||
| Current Valuation | 1.65 M | ||||
| Shares Outstanding | 4.34 M | ||||
| Shares Owned By Insiders | 7.06 % | ||||
| Shares Owned By Institutions | 5.37 % | ||||
| Number Of Shares Shorted | 284.03 K | ||||
| Price To Book | 0.99 X | ||||
| Price To Sales | 57.46 X | ||||
| Revenue | 156.42 K | ||||
| Gross Profit | (1.36 K) | ||||
| EBITDA | (6.61 M) | ||||
| Net Income | (6.74 M) | ||||
| Cash And Equivalents | 21.76 K | ||||
| Total Debt | 224.3 K | ||||
| Current Ratio | 0.04 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (6.25 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (2.61) X | ||||
| Target Price | 20.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 8.99 M | ||||
| Total Asset | 5.48 M | ||||
| Retained Earnings | (18.53 M) | ||||
| Working Capital | 4.21 M | ||||
| Net Asset | 5.48 M |
About Virax Biolabs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virax Biolabs Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virax Biolabs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virax Biolabs Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.